Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A.
Mouri A, Kisohara A, Morita R, Ko R, Nakagawa T, Makiguchi T, Isobe K, Ishikawa N, Kondo T, Akiyama M, Bessho A, Honda R, Yoshimura K, Kagamu H, Kato S, Kobayashi K, Kaira K, Maemondo M. Mouri A, et al. Among authors: kagamu h. ESMO Open. 2024 Oct;9(10):103939. doi: 10.1016/j.esmoop.2024.103939. Epub 2024 Oct 11. ESMO Open. 2024. PMID: 39395258 Free PMC article. Clinical Trial.
A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
Kaira K, Mouri A, Kato S, Yoshimura K, Kagamu H, Kobayashi K. Kaira K, et al. Among authors: kagamu h. BMC Cancer. 2020 Oct 6;20(1):961. doi: 10.1186/s12885-020-07406-y. BMC Cancer. 2020. PMID: 33023530 Free PMC article. Clinical Trial.
Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
Mouri A, Kaira K, Shiono A, Yamaguchi O, Murayama Y, Kobayashi K, Kagamu H. Mouri A, et al. Among authors: kagamu h. Thorac Cancer. 2019 Apr;10(4):1005-1008. doi: 10.1111/1759-7714.13022. Epub 2019 Mar 11. Thorac Cancer. 2019. PMID: 30859745 Free PMC article.
Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Miura Y, Shiono A, Nishihara F, Murayama Y, Noda SE, Kato S, Kobayashi K, Kagamu H. Yamaguchi O, et al. Among authors: kagamu h. Thorac Cancer. 2019 Apr;10(4):992-1000. doi: 10.1111/1759-7714.13044. Epub 2019 Mar 19. Thorac Cancer. 2019. PMID: 30888716 Free PMC article.
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
Miura Y, Mouri A, Kaira K, Yamaguchi O, Shiono A, Hashimoto K, Nishihara F, Shinomiya S, Akagami T, Murayama Y, Abe T, Noda SE, Kato S, Kobayashi K, Kagamu H. Miura Y, et al. Among authors: kagamu h. Thorac Cancer. 2020 May;11(5):1280-1287. doi: 10.1111/1759-7714.13394. Epub 2020 Mar 11. Thorac Cancer. 2020. PMID: 32160383 Free PMC article.
194 results